| 臺大學術典藏 |
2022-04-25T06:44:23Z |
Deep learning–assisted burn wound diagnosis: Diagnostic model development Study
|
Chang C.W;Lai F;Christian M;Chen Y.C;Hsu C;Chen Y.S;Chang D.H;Roan T.L;Yu Y.C.; Chang C.W; Lai F; Christian M; Chen Y.C; Hsu C; Chen Y.S; Chang D.H; Roan T.L; Yu Y.C.; FEI-PEI LAI |
| 臺大學術典藏 |
2022-04-25T06:12:30Z |
Microbial Phosphorylation Product of Hesperetin by Bacillus subtilis BCRC 80517 Improves Oral Bioavailability in Rats
|
Wang S.-T;Chen J.-A;Hsu C;Su N.-W.; Wang S.-T; Chen J.-A; Hsu C; Su N.-W.; NAN-WEI SU |
| 臺大學術典藏 |
2022-04-07T01:43:07Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; TSUNG-HAO LIU; Chen C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-04-01T05:42:24Z |
Practice guideline adherence and health care outcomes - Use of prophylactic antibiotics during surgery in Taiwan
|
Hsu C.; SHOU-HSIA CHENG |
| 臺大學術典藏 |
2022-03-29T07:00:05Z |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma
|
Shen Y.-C.; Ou D.-L.; Hsu C.; Lin K.-L.; Chang C.-Y.; CHING-YU LIN; Liu S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-03-15T05:39:31Z |
The first two lines of chemotherapy for anthracycline-naive metastatic breast cancer: A comparative study of the efficacy of anthracyclines and non-anthracyclines
|
WEI-WU CHEN; Chang D.-Y.; Huang S.-M.; Lin C.-H.; Hsu C.; Lin M.-H.; Huang C.-S.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2022-03-15T05:39:18Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang F.-C.; WEI-WU CHEN; Huang T.T.-M.; Lin W.-C.; Liu J.-S.; Chiang W.-C.; Chen Y.-M.; Hsu C.; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2022-03-10T07:58:37Z |
Epithelioid Trophoblastic Tumor Around an Abdominal Cesarean Scar: A Pathologic and Molecular Genetic Analysis
|
Hsiue E.H.-C.; Hsu C.; LI-HUI TSENG; Lu T.-P.; Kuo K.-T. |
| 臺大學術典藏 |
2022-03-10T03:55:00Z |
Comparison of GATK and DeepVariant by trio sequencing
|
Lin Y.-L.; Chang P.-C.; Hsu C.; Hung M.-Z.; Chien Y.-H.; Hwu W.-L.; Lai F.P.; NI-CHUNG LEE |
| 臺大學術典藏 |
2022-03-08T03:44:07Z |
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials
|
SHIH-HUNG YANG; Kuo Y.-H.; Tien Y.-W.; Hsu C.; Hsu C.-H.; Kuo S.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-03-08T03:44:06Z |
Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy
|
Kuo Y.-H.; Lin C.-H.; Shau W.-Y.; Chen T.-J.; SHIH-HUNG YANG; Huang S.-M.; Hsu C.; Lu Y.-S.; Cheng A.-L. |
| 臺大學術典藏 |
2022-03-08T03:44:05Z |
Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer
|
SHIH-HUNG YANG; Kuo T.-C.; Wu H.; Guo J.-C.; Hsu C.; Hsu C.-H.; Tien Y.-W.; Yeh K.-H.; Cheng A.-L.; Kuo S.-H. |
| 臺大學術典藏 |
2022-03-08T03:44:02Z |
A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma�VTCOG T1211 study
|
Chiang N.-J.; Tsai K.K.; Hsiao C.-F.; SHIH-HUNG YANG; Hsiao H.-H.; Shen W.-C.; Hsu C.; Lin Y.-L.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2022-03-08T03:44:02Z |
Low-dose nab-paclitaxel-based combination chemotherapy in heavily pretreated pancreatic cancer patients
|
SHIH-HUNG YANG; Guo J.-C.; Hsu C.; Kuo S.-H.; Tien Y.-W.; Cheng A.-L.; Yeh K.-H. |
| 臺大學術典藏 |
2022-03-08T03:44:01Z |
Multicentre, phase II study of gemcitabine and S-1 in patients with advanced biliary tract cancer: TG1308 study
|
Chiang N.-J.; Chen M.-H.; SHIH-HUNG YANG; Hsu C.; Yen C.-J.; Tsou H.-H.; Su Y.-Y.; Chen J.-S.; Shan Y.-S.; Chen L.-T. |
| 臺大學術典藏 |
2022-03-04T06:53:38Z |
Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
|
Lin Y.-Y.; CHING-TING TAN; Chen C.-W.; Ou D.-L.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2022-03-04T03:48:02Z |
Spectrum of cancer patients receiving renal biopsy
|
Chang F.-C.; Chen T.W.-W.; Huang T.T.-M.; WEI-CHOU LIN; Liu J.-S.; Chiang W.-C.; Chen Y.-M.; Hsu C.; Yeh K.-H.; Chu T.-S. |
| 臺大學術典藏 |
2022-02-23T02:12:30Z |
Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma
|
Ch'Ang H.-J.; Hsu C.; CHIEN-HUNG CHEN; Chang Y.-H.; Chang J.S.; Chen L.-T. |
| 臺大學術典藏 |
2022-02-23T02:12:27Z |
Comparison of characteristics and transarterial chemoembolization outcomes in patients with unresectable hepatocellular carcinoma and different viral etiologies
|
Chen B.-B.; Shih I.-L.; Wu C.-H.; Hsu C.; CHIEN-HUNG CHEN; Shih T.T.-F.; Liu K.-L.; Liang P.-C. |
| 臺大學術典藏 |
2022-02-23T02:12:26Z |
Consensus development from the 5th asia-pacific primary liver cancer expert meeting (APPLE 2014)
|
Hsu C.; Chen B.-B.; CHIEN-HUNG CHEN; Ho M.-C.; Cheng J.C.-H.; Kokudo N.; Murakami T.; Yeo W.; Seong J.; Jia J.-D.; Han K.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-23T02:12:26Z |
Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma
|
Chang M.-C.; CHIEN-HUNG CHEN; Liang J.-D.; Tien Y.-W.; Hsu C.; Wong J.-M.; Chang Y.-T. |
| 臺大學術典藏 |
2022-02-23T02:12:24Z |
Management consensus guideline for hepatocellular carcinoma: 2016 updated by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Lu S.-N.; Wang J.-H.; Su C.-W.; Wang T.-E.; Dai C.-Y.; CHIEN-HUNG CHEN; Chen R.-C.; Yang S.-S.; Hung C.-F.; Huang S.-F.; Liao L.-Y.; Huo T.-I.; Wu C.-C.; Lee P.-H.; Ting C.-T.; Lee W.-C.; Chau G.-Y.; Wang C.-C.; Lee K.-T.; Huang Y.-H.; Ho M.-C.; Lin S.-M.; Huang G.-T.; Chen K.-Y.; Lin X.-Z.; Hwang J.-I.; Chiou Y.-Y.; Wang C.-K.; Hu J.-T.; Chen S.-C.; Liang P.-C.; Lee R.-C.; Wu D.-K.; Lin C.-Y.; Lin C.-C.; Cheng A.-L.; Hsu C.; Chao Y.; Chen L.-T.; Wang P.-M.; Wang P.-M.; Hong J.-H.; Hsu H.-C.; Chen S.-W.; Leung S.W.; Cheng J.C.-H.; Wu J.-C.; Wu C.-Y.; Hsu Y.-C.; Hsu C.-W.; Ni Y.-H.; Lin C.-L.; Local ablation group, Surveillance group, Diagnosis group, Staging group, Surgery group, TACE/TARE/HAI group, Target therapy/systemic therapy group, Radiotherapy group, Prevention group, Drafting group |
| 臺大學術典藏 |
2022-02-23T02:12:20Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; CHIEN-HUNG CHEN; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-02-23T02:12:19Z |
Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy
|
Shen Y.-C.; Yeh C.-P.; Jeng Y.-M.; Hsu C.; Hsu C.-H.; Lin Z.-Z.; Shao Y.-Y.; Lu L.-C.; Liu T.-H.; CHIEN-HUNG CHEN; Cheng A.-L. |
| 臺大學術典藏 |
2022-02-22T05:34:22Z |
Phase II study of concomitant thalidomide during radiotherapy for hepatocellular carcinoma
|
Ch'Ang H.-J.; Hsu C.; CHIEN-HUNG CHEN; Chang Y.-H.; Chang J.S.; Chen L.-T. |
